A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- 09 Mar 2017 New trial record